The mRNA-4157 vaccine is one of Moderna's flagship cancer therapies currently in clinical trials. This vaccine is customized for each patient by sequencing their tumor DNA to identify mutations. The identified mutations are then encoded into mRNA, creating a vaccine that instructs the patient's immune system to target and destroy cancer cells harboring these mutations.